Johnson & Johnson (J&J) and Procter & Gamble (P&G) both reported earnings that surpassed Wall Street expectations for the final quarter of 2024. J&J posted adjusted earnings per share (EPS) of $2.04, exceeding the $1.99 estimate, with revenue reaching $22.52 billion, a 5.3% year-over-year increase. Strong sales of cancer drugs, including Darzalex, which rose 20% to $3.08 billion, and overall oncology drug sales up 12%, contributed significantly to the results. However, J&J's net income declined 17% year-over-year to $3.43 billion, and Stelara sales dropped 14.7% due to generic competition. Looking ahead, J&J provided a 2025 adjusted operational EPS guidance of $10.75 to $10.95. Meanwhile, P&G reported adjusted EPS of $1.88, beating the $1.86 estimate, and revenue of $21.88 billion, up 2.1% year-over-year. Organic sales grew 3%, driven by demand for household staples such as toilet paper and laundry products. P&G's gross margin reached 52.4%, and the company reported net income of $4.63 billion. It maintained its fiscal 2025 guidance, forecasting core EPS growth of 5-7% and organic revenue growth of 3-5%. The company also highlighted strong performance in its baby, feminine, and family care categories.